Pfizer announced this week that, if development of its pill to treat Covid-19 infection continues at the current pace, and if regulatory approval is quick, the medication could be on the market in the US by the end of 2021.
Pfizer launched an early trial in March of the oral antiviral which tackles Sars-CoV-2, the coronavirus that causes Covid-19, by limiting the availability of the enzyme protease which the virus needs to replicate.
Continue reading https://on.rt.com/b7b5